Skip to main content
  • Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis

    Mundipharma and Cidara Therapeutics announced that the European Commission (EC) has now adopted the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) recommendation to grant Orphan Drug Designation (ODD) to rezafungin, a novel, once-weekly echinocandin, for the treatment of invasive candidiasis (IC).

  • New Study Concludes Xlear Kills and/or Deactivates SARS-CoV-2

    A new in vitro study done collaboratively by Utah State University and Northwestern University finds Xlear components (grapefruit seed extract and xylitol) significantly eliminates SARS-CoV-2, the virus that causes COVID-19. The imaging research study component was performed at the BioCryo facility of Northwestern University’s NUANCE Center.

  • Merck winds up development of COVID-19 vaccine

    MSD outside the United States and Canada announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110. This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines.

    admin Tue, 01/26/2021 - 16:56
  • Massey researchers review geographic factors that affect HPV vaccination rates

    Human papillomavirus (HPV) is the most common sexually transmitted infection, with an estimated 79 million Americans currently infected with the virus, according to the Centers for Disease Control and Prevention. If a high-risk HPV infection does not go away, it can lead to the development of a variety of cancers, including 91% of all cervical cancers, 70% of oropharyngeal cancers and cancers of the vulva, vagina, penis and anus.

    admin Mon, 01/25/2021 - 16:05
  • New combo therapy for head and neck cancer : Researcher

    Head and neck cancer is the sixth most common cancer worldwide, and while effective treatments exist, sadly, the cancer often returns.

    Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better.

    Since they're using a Food and Drug Administration-approved drug to do it, this could help humans sooner than later.

    admin Mon, 01/25/2021 - 15:58
  • Focus on management of adverse events in COVID-19 vaccination

    The operation guidelines prepared by the Central Government for the COVID-19 vaccination programme currently underway, provides a detailed roadmap to ensure a robust surveillance system to monitor adverse events post immunization and better understand the safety profile of the vaccines.

    admin Sat, 01/23/2021 - 17:06
  • Inter-sectorial Convergence for COVID 19 vaccination

    As many as 19 Ministries and Departments of the Government of India are involved in the implementation of the national vaccination campaign that is currently underway to overcome the COVID-19 pandemic.

    admin Sat, 01/23/2021 - 16:59
  • Alembic Pharmaceuticals receives USFDA Approval for Midodrine Hydrochloride Tablets USP

    Alembic Pharmaceuticals Limited announced it has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), ProAmatine Tablets, 2.5 mg, 5 mg, and 10 mg, of Takeda Pharmaceuticals USA, Inc. (Takeda). Midodrine Hydrochloride Tablets are indicated for the treatment of symptomatic orthostatic hypotension (OH).

    admin Sat, 01/23/2021 - 15:51
  • FDA approves Cabenuva as long acting regimen of HIV treatment

    ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc with Pfizer Inc. and Shionogi Limited as shareholders, announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults.

    admin Fri, 01/22/2021 - 12:24
  • Hematopoietic Stem Cell Transplants May Provide Long-Term Benefit for People with MS

    A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment.

    admin Thu, 01/21/2021 - 17:18
Subscribe to Pharma News